MolecularMD Announces Issuance of Patent Covering Methods for Therapeutic Resistance Monitoring in Lung Cancer Patients
December 09, 2011 07:00 ET
|
MolecularMD
PORTLAND, OR--(Marketwire - Dec 9, 2011) - MolecularMD Corp. today announces the issuance of a patent titled "Methods and Compositions for Detecting a Drug Resistant EGFR Mutant." The newly issued...
Atossa Genetics Acquires Rights to Patents Covering a Novel Screening Test for Breast Cancer From the Dr. Susan Love Research Foundation
July 13, 2011 08:30 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwire - Jul 13, 2011) - Atossa Genetics, Inc., a privately-held health care company focused on the development and marketing of novel cellular and molecular diagnostic risk...
Atossa Genetics Completes $6.6 Million Over-Subscribed Private Placement
June 27, 2011 08:00 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwire - Jun 27, 2011) - Atossa Genetics, Inc., a privately-held health care company focused on the development and marketing of novel cellular and molecular diagnostic risk...
Atossa Genetics, Inc. and HLB, LLC Announce Partnership to Manufacture Atossa's Patented, FDA-Cleared MASCT System for Breast Cancer Risk Assessment
May 03, 2011 08:30 ET
|
Atossa Genetics, Inc.
SEATTLE, WA and CHICAGO, IL--(Marketwire - May 3, 2011) - Atossa Genetics, Inc., a privately-held health care company focused on the development and marketing of novel cellular and molecular...
Atossa Genetics Appoints Tim Hunkapiller, Ph.D., to Its Scientific Advisory Board
April 14, 2011 11:28 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwire - Apr 14, 2011) - Atossa Genetics, Inc., a privately-held health care company focused on the development and marketing of novel cellular and molecular diagnostic risk...
Steven C. Quay, M.D., Ph.D., of Atossa Genetics Elected as a Fellow of the College of American Pathologists
March 14, 2011 08:00 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwire - March 14, 2011) - Atossa Genetics, Inc., a privately-held health care company focused on the development and marketing of novel cellular and molecular diagnostic risk...
MolecularMD Corp. Obtains Exclusive License From NYU and MSKCC for BRAF Melanoma Assay
October 18, 2010 07:00 ET
|
MolecularMD
PORTLAND, OR--(Marketwire - October 18, 2010) - MolecularMD Corp. announced today that it has entered into a licensing agreement with New York University (NYU) and Memorial Sloan-Kettering Cancer...
Atossa Genetics, Inc. Announces Filing of S-1 Registration Statement
October 01, 2010 09:30 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwire - October 1, 2010) - Atossa Genetics, Inc., a privately-held healthcare company focused on the development and marketing of novel cellular and molecular diagnostic risk...
Atossa Genetics, Inc. Appoints Edward Sauter, M.D., Ph.D., to Its Scientific Advisory Board
February 25, 2010 11:00 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwire - February 25, 2010) - Atossa Genetics, Inc., a privately-held healthcare company focused on the development and marketing of novel cellular and molecular diagnostic...
Atossa Genetics, Inc. Launches Corporate Web Site Featuring New FDA-Approved Breast Cancer Risk Assessment Test
February 08, 2010 08:30 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwire - February 8, 2010) - Atossa
Genetics, Inc., a privately-held healthcare company focused on the
development and marketing of novel cellular and molecular diagnostic...